Turkish officers probe Teva for allegedly gaming patent system, disparaging rivals

Ed’s tales discover prescription drug pricing, affordability and entry, as properly points surrounding patents, litigation, and laws. He can be the creator of the morning Pharmalittle publication and the afternoon Pharmalot publication.

Turkish antitrust regulators are investigating Teva Pharmaceutical, the world’s largest generic drugmaker, for allegedly manipulating the patent system and making deceptive statements to well being care authorities in regards to the security and effectiveness of rival medicines.

The firm engaged in “various practices … that may have been aimed at making it more difficult for competitors to enter the market,” in line with Turkey’s Competition Board, which is called Rekabet Kurumu and which launched the probe earlier this month however disclosed the choice final Friday on its website.

The regulator didn’t point out a selected drug, however a Teva spokesperson wrote us that the investigation is much like a probe by the European Commission that, two years in the past, ended with the corporate paying a $503 million nice for delaying competitors to its blockbuster Copaxone a number of sclerosis medication. The case is at present underneath attraction earlier than the European Court.